标题
The molecular pathology of ovarian serous borderline tumors
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 27, Issue suppl 1, Pages i16-i19
出版商
Oxford University Press (OUP)
发表日期
2016-05-02
DOI
10.1093/annonc/mdw089
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
- (2015) David M Gershenson et al. BRITISH JOURNAL OF CANCER
- Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
- (2015) Rachel N. Grisham et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
- (2015) I. Vasconcelos et al. ONCOLOGIST
- BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors
- (2014) Felix Zeppernick et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Monoclonal Origin of Peritoneal Implants and Lymph Node Deposits in Serous Borderline Ovarian Tumors (s-BOT) With High Intratumoral Homogeneity
- (2014) Lars-Christian Horn et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
- (2013) Dinka Sundov et al. Diagnostic Pathology
- Whole exome sequence analysis of serous borderline tumors of the ovary
- (2013) Jeff Boyd et al. GYNECOLOGIC ONCOLOGY
- KRAS(but notBRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma
- (2013) Yvonne T Tsang et al. JOURNAL OF PATHOLOGY
- Mutational analysis ofBRAFandKRASin ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants
- (2013) Laura Ardighieri et al. JOURNAL OF PATHOLOGY
- Ovarian Serous Tumors of Low Malignant Potential With Nodal Low-grade Serous Carcinoma
- (2012) Bojana Djordjevic et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
- (2012) Rachel N. Grisham et al. CANCER
- Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- (2012) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Borderline Tumors of the Ovary: Clinical Course and Prognostic Factors
- (2012) Nina Ewald-Riegler et al. ONKOLOGIE
- BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
- (2010) Kwong-Kwok Wong et al. AMERICAN JOURNAL OF PATHOLOGY
- v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior
- (2010) Marjolijn B. Verbruggen et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas
- (2010) Peter W. Schlosshauer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors
- (2010) Ildikó Vereczkey et al. PATHOLOGY & ONCOLOGY RESEARCH
- Lymph Node Involvement in Ovarian Serous Tumors of Low Malignant Potential: A Clinicopathologic Study of Thirty-six Cases
- (2009) Bojana Djordjevic et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
- (2008) M. S. Anglesio et al. MOLECULAR CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started